TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19330931
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus GG (LGG) supplementation with standard triple therapy (amoxicillin 25 mg/kg twice per day, clarithromycin 10 mg/kg twice per day, omeprazole 0.5 mg/kg twice per day)
Study: 19330931
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with standard triple therapy (amoxicillin 25 mg/kg twice per day, clarithromycin 10 mg/kg twice per day, omeprazole 0.5 mg/kg twice per day)
Study: 2723127
Drug: Buprenorphine 0.3
Normalized name: buprenorphine 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.3 mg and saline
Study: 2723127
Drug: Buprenorphine 0.3
Normalized name: buprenorphine 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.3 mg and naloxone 0.6 mg
Study: 2723127
Drug: Buprenorphine 0.3
Normalized name: buprenorphine 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.3 mg and naloxone 0.45 mg
Study: 2723127
Drug: Buprenorphine 0.3
Normalized name: buprenorphine 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.3 mg and naloxone 0.3 mg
Study: 2723127
Drug: Buprenorphine 0.3
Normalized name: buprenorphine 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.3 mg and naloxone 0.15 mg
Study: 22271702
Drug: Outpatient, oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient, oral amoxicillin plus ciprofloxacin
Study: 22271702
Drug: Continued standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued standard treatment (intravenous antimicrobial therapy)
Study: 20010073
Drug: Planned treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Planned treatment interruptions (PTI)
Study: 17187491
Drug: Valproate combined
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate combined with lithium or antipsychotic drugs
Study: 17187491
Drug: Valproate (serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate (serum levels 75-99 microg/ml)
Study: 2129317
Drug: oral nitrate
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral nitrate therapy
Study: 7275281
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of stored serum Biseko on the day of operation and the first postoperative day
Study: 25791462
Drug: OCP combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCP combined with metformin (n=25)
Study: 22717305
Drug: 5-hour preprocedural
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hour preprocedural intravenous hydration with isotonic saline (5h-HS)
Study: 22717305
Drug: 20-hour preprocedural
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-hour preprocedural intravenous hydration with isotonic saline (20h-HS)
Study: 21129991
Drug: Biatrial reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biatrial reduction with reef‐imbricate suture technique and aggressive postoperative pharmacological therapy
Study: 20027097
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg intravenously)
Study: 17474814
Drug: Atomoxetine 40
Normalized name: atomoxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine 40 to 120 mg/day
Study: 15191378
Drug: Gatifloxacin 400
Normalized name: gatifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 400 mg once-daily for 5-10 days
Study: 15191378
Drug: Co-amoxiclav 500
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav 500 mg + clavulanic acid 125 mg three-times-daily for 5-10 days
Study: 9491502
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of a three-component acellular pertussis vaccine
Study: 9491502
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of a five-component acellular pertussis vaccine
Study: 9491502
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of a three-component acellular pertussis vaccine
Study: 9491502
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of a five-component acellular pertussis vaccine
Study: 8141107
Drug: Three-drug combination
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug combination (ODA)
Study: 8141107
Drug: Two-drug combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug combination (OD)
Study: 3320274
Drug: 100% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% oxygen at 2 ATA for 90 minutes daily for 20 sessions
Study: 3320274
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy with air using a simulated compression procedure
Study: 30166311
Drug: Online cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online cognitive behaviour therapy for insomnia (CBT-I)
Study: 24830830
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of fish oil
Study: 24830830
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of fish oil plus a multivitamin
Study: 24830830
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of fish oil plus a multivitamin
Study: 24830830
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g fish oil multivitamin combination
Study: 16148589
Drug: travoprost 0.004%/timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: travoprost 0.004%/timolol 0.5% fixed combination
Study: 16148589
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of travoprost 0.004% and timolol 0.5%
Study: 10049962
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing (ODD) of gentamicin at 4 mg/kg
Study: 10049962
Drug: Twice-daily dosing
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily dosing (TDD) of gentamicin at 2.5 mg/kg every 12 hours
Study: 7747292
Drug: New empirical
Approvals — FDA: no, EMA: no, PMDA: no
Description: New empirical antibiotic regimen
Study: 2040893
Drug: Agar methods
Normalized name: Agar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agar methods with 64 micrograms/ml breakpoint
Study: 12780716
Drug: G. biloba
Approvals — FDA: no, EMA: no, PMDA: no
Description: G. biloba extract 40 mg three times daily
Study: 8404553
Drug: Epinephrine-injection technique
Normalized name: epinephrine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine-injection technique
Study: 27449641
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus dexamethasone (20 mg iv from day 1 to day 5, and 10 mg iv from day 6 to day 10)
Study: 27449641
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment without dexamethasone
Study: 20222964
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment feasibility as perceived by physicians
Study: 20222964
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment feasibility as perceived by nurses
Study: 20222964
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment feasibility as perceived by patients
Study: 20222964
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment feasibility as perceived by relatives
Study: 16152821
Drug: Qingxin Capsule
Normalized name: SILICON DIOXIDE 14 g in 100 g / .ALPHA.-TOCOPHEROL ACETATE 0.1 g in 100 g / SODIUM PYROPHOSPHATE 0.5 g in 100 g DENTAL PASTE, DENTIFRICE [Mastikis Qingxin Care Mastic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingxin Capsule (QC)
Study: 16152821
Drug: AT1R AC
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT1R AC plus CC gene type in EH patients
Study: 16152821
Drug: AA gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AA gene type vs AA plus CC gene type
Study: 16152821
Drug: Gene type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene type and hypotensive effect of treatments
Study: 11008854
Drug: Two treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two treatments focused on improving interpersonal relationships with social skills training
Study: 11008854
Drug: Two treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two treatments focused on improving interpersonal relationships without social skills training
Study: 8880291
Drug: Clarithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (250 mg twice a day for 5 days)
Study: 8384658
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg once a day for 3 days)
Study: 2050329
Drug: Torasemide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide (10 mg/day)
Study: 2050329
Drug: Furosemide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (25 mg/day)
Study: 6630285
Drug: Doxorubicin only
Normalized name: Doxorubicin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin only (60 mg/m2)
Study: 6630285
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m2) with tocopherol (200 mg i.m. 6 h before treatment) and nifedipine (60 mg p.o. daily from 2 days before infusion)
Study: 31805483
Drug: Desensitising cream
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desensitising cream containing NaF 9,000 ppm associated with 20% nanohydroxyapatite
Study: 30658483
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (3200 IU daily for 3 months)
Study: 30658483
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for 3 months)
Study: 17391816
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml dose of 7-valent pneumococcal conjugate vaccine
Study: 17391816
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml dose of 23-valent pneumococcal polysaccharide vaccine
Study: 10220541
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blocker treatment in high risk patients requiring diuretics
Study: 8907622
Drug: Chloraminophene capsules
Normalized name: Chloraminophen
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloraminophene capsules
Study: 8907622
Drug: Chloraminophene tablets
Normalized name: Chloraminophen
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloraminophene tablets
Study: 30176835
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) as add-on to antidepressant treatment
Study: 30176835
Drug: Placebo as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as add-on to antidepressant treatment
Study: 27012420
Drug: Combined vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vitamin E and selenium (200 µg/d L-selenomethionine)
Study: 27012420
Drug: Selenium alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium alone (200 µg/d L-selenomethionine)
Study: 20398269
Drug: Autologous platelet
Normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet concentrate injections
Study: 3203706
Drug: Concomitant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant treatment with 10 mg benazepril and 40 mg furosemide
Study: 2407810
Drug: Fluorouracil (FUra)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (FUra) administered intravenously at a dose of 370 mg/m2/d for 5 days
Study: 2407810
Drug: Fluorouracil (FUra)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (FUra) plus high-dose continuous infusion leucovorin calcium (500 mg/m2/d)
Study: 971163
Drug: Mepiprazole hydrochloride
DrugBank: Mepiprazole (DB09197)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepiprazole hydrochloride (therapeutic preparation)
Study: 21161651
Drug: Cystone® (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cystone® (2 tablets BID for 1 year)
Study: 17597461
Drug: Levamisole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (150 mg single dose as adjunct to quinine)
Study: 17597461
Drug: Quinine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine treatment alone
Study: 15234038
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of perirectal seeds ≤2.0 mm from rectal wall
Study: 15234038
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of perirectal seeds 2‐4 mm from rectal wall
Study: 11435528
Drug: Ca-HMB (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca-HMB (3 g/d)
Study: 7914306
Drug: PRP-T vaccine
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-T vaccine (Hib conjugate vaccine) given by separate injection according to an accelerated 2, 3, and 4 month schedule without a booster dose in the second year of life.
Study: 7914306
Drug: Intention-to-treat analysis
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intention-to-treat analysis of PRP-T vaccine.
Study: 7914306
Drug: PRP-T vaccine
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-T vaccine (Hib conjugate vaccine) with follow-up until November 1, 1993.
Study: 3056331
Drug: Thymopentin (TP‐5)
Normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (TP‐5) 50 mg subcutaneously two hours preoperatively
Study: 3056331
Drug: Thymopentin (TP‐5)
Normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (TP‐5) 50 mg subcutaneously two hours preoperatively and 48 hours postoperatively
Study: 27306255
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (5 ± 2 mg for 24 hours at 2 mL/h)
Study: 25255724
Drug: Ulinastatin (UTI)
Normalized name: phenazopyridine hydrochloride Oral Tablet [UTI Relief]
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (UTI) - intravenous infusion of 5000 IU/kg before anesthesia and at the start of surgery
Study: 22117989
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg orally three times daily) plus fenofibrate (200 mg orally once daily)
Study: 22117989
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg orally three times daily) plus placebo
Study: 20183462
Drug: Herbal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal treatment for acute hepatitis
Study: 16606971
Drug: Bortezomib (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1.3 mg/m2) administered on days 1, 4, 8, and 11 of a 3-week cycle
Study: 11316640
Drug: Salmeterol 42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 42 microg twice daily
Study: 11316640
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide 36 microg four times daily
Study: 8148464
Drug: Development of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Development of additional approaches to prevention and treatment
Study: 3555597
Drug: 0.05% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% tretinoin cream applied nightly after 5% 5-fluorouracil (5-FU) cream applied twice daily
Study: 3555597
Drug: Control cream
Normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control cream applied nightly after 5% 5-fluorouracil (5-FU) cream applied twice daily
Study: 28753486
Drug: Empagliflozin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (both doses)
Study: 25664215
Drug: Milnacipran (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran (100-200 mg/d, dosed twice a day)
Study: 16111420
Drug: Partial cochlear
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial cochlear implant insertion (8 electrodes)
Study: 16111420
Drug: Full cochlear
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full cochlear implant insertion
Study: 379955
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metronidazole and emetine
Study: 379955
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (including antiamoebic drugs)
Study: 27548998
Drug: Fractional carbon
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional carbon dioxide laser combined with betamethasone and salicylic acid solution
Study: 27548998
Drug: Betamethasone and
Normalized name: betamethasone and mydriatics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone and salicylic acid solution
Study: 27626365
Drug: Radical radiotherapy
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical radiotherapy with hormones
Study: 27626365
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (other treatments)
Study: 25383998
Drug: DVD presentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DVD presentation administered by a community mental health educator
Study: 16255877
Drug: anti-CD(4), CD(8)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-CD(4), CD(8) monoclonal antibodies combined with cyclosporine A
Study: 10354213
Drug: Hyperglycaemia (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemia (12 mmol L‐1)
Study: 10354213
Drug: Euglycaemia (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycaemia (4 mmol L‐1)
Study: 7867053
Drug: 1% chlorhexidine-fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine-fluoride gel (GCHXF)
Study: 17917503
Drug: Darusentan (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darusentan (300 mg)
Study: 1789394
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (low dose)
Study: 7056273
Drug: Tolmesoxide (300‐900mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolmesoxide (300‐900mg daily)
Study: 27764682
Drug: Milk containing
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk containing 2.5ppm fluoride daily (T1)
Study: 27764682
Drug: Milk containing
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk containing 5.0ppm fluoride daily (T3)
Study: 27764682
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (T5)
Study: 20180429
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C tablets plus intramuscular chymotrypsin (Control)
Study: 11471263
Drug: Rectal thermometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal thermometry
Study: 6118964
Drug: Prazosin 0.5
Normalized name: prazosin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin 0.5 mg
Study: 6118964
Drug: Salbutamol 1
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 1 mg
Study: 24107738
Drug: Spironolactone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25 mg, increased to 50 mg if needed after 4 weeks)
Study: 15103544
Drug: Subcutaneous epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous epoetin beta (NeoRecormon) to maintain target Hb levels of 13‐15 g/dl
Study: 15103544
Drug: Current practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current practice (no epoetin therapy until Hb levels decline below 10.5 g/dl)
Study: 15103544
Drug: Subcutaneous epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous epoetin beta (NeoRecormon)
Study: 11328423
Drug: Clomiphene citrate,
Normalized name: ClomiPHENE Citrate, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene citrate, 50 mg/day, orally
Study: 7992099
Drug: Low-dose cytosine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytosine arabinoside and IFN-alpha
Study: 16813178
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of heloperidol
Study: 10740947
Drug: Treatment designed
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment designed to reduce risk of relapse
Study: 1533504
Drug: Inhaled bronchodilators
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bronchodilators (salbutamol and ipratropium bromide)
Study: 31576916
Drug: Low- to
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low- to moderate-intensity aerobic exercise plus standard medical treatment
Study: 31576916
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment without exercise intervention
Study: 24602005
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral bolus dose of 6,8,10,3',5'‐(13)C5‐C3G
Study: 22677568
Drug: Acacia fiber,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acacia fiber, psyllium fiber, and fructose (AFPFF) 16.8 g daily